Structural principles of tumor necrosis factor superfamily signaling

Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs

(2017) Heather Torrey et al.   Science Signaling

Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs

(2017) Heather Torrey et al.   Science Signaling

Onto better TRAILs for cancer treatment

(2016) D de Miguel et al.   CELL DEATH AND DIFFERENTIATION

Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF–TNF-RII binding in rheumatoid arthritis

(2016) Dao Xuan Nguyen et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Structural Basis and Functional Role of Intramembrane Trimerization of the Fas/CD95 Death Receptor

(2016) Qingshan Fu et al.   MOLECULAR CELL

TNFR-Associated Factor-2 (TRAF2): Not Only a Trimer

(2015) Arianna Ceccarelli et al.   BIOCHEMISTRY

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity

(2014) Jonathan D. Graves et al.   CANCER CELL

Dominant Negative Effects of Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL) Receptor 4 on TRAIL Receptor 1 Signaling by Formation of Heteromeric Complexes

(2014) Simon Neumann et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells

(2014) M H Tuthill et al.   ONCOGENE

Structural studies of postentry restriction factors reveal antiparallel dimers that enable avid binding to the HIV-1 capsid lattice

(2014) David C. Goldstone et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanistic Basis for Functional Promiscuity in the TNF and TNF Receptor Superfamilies: Structure of the LIGHT:DcR3 Assembly

(2014) Weifeng Liu et al.   STRUCTURE

Molecular Basis of NF-κB Signaling

(2013) Johanna Napetschnig et al.   Annual Review of Biophysics

A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2013) Luis Paz-Ares et al.   Journal of Thoracic Oncology

Dimerization of LT R by LT 1 2 is necessary and sufficient for signal transduction

(2013) J. Sudhamsu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Homogeneous Expansion of Human T-Regulatory Cells Via Tumor Necrosis Factor Receptor 2

(2013) Yoshiaki Okubo et al.   Scientific Reports

TNF Receptor 2 and Disease: Autoimmunity and Regenerative Medicine

(2013) Denise L. Faustman et al.   Frontiers in Immunology

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

(2012) H. L. Kindler et al.   ANNALS OF ONCOLOGY

Crystal Structure of Human RANKL Complexed with Its Decoy Receptor Osteoprotegerin

(2012) X. Luan et al.   JOURNAL OF IMMUNOLOGY

The Tumor Necrosis Factor Receptor Stalk Regions Define Responsiveness to Soluble versus Membrane-Bound Ligand

(2012) C. Richter et al.   MOLECULAR AND CELLULAR BIOLOGY

Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity

(2012) M Siegemund et al.   Cell Death & Disease

Crystallographic and Mutational Analysis of the CD40-CD154 Complex and Its Implications for Receptor Activation

(2011) Hyun-Jung An et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Decoy Strategies: The Structure of TL1A:DcR3 Complex

(2011) Chenyang Zhan et al.   STRUCTURE

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

(2010) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

(2010) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Structural and Functional Insights of RANKL-RANK Interaction and Signaling

(2010) C. Liu et al.   JOURNAL OF IMMUNOLOGY

Asymmetric Recruitment of cIAPs by TRAF2

(2010) Peter D. Mace et al.   JOURNAL OF MOLECULAR BIOLOGY

Crystal Structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 Complexes: Affinity, Specificity, and Regulation

(2010) Chao Zheng et al.   MOLECULAR CELL

Hexagonal assembly of a restricting TRIM5  protein

(2010) B. K. Ganser-Pornillos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Solution of the Structure of the TNF-TNFR2 Complex

(2010) Y. Mukai et al.   Science Signaling

Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins

(2010) B Schneider et al.   Cell Death & Disease

Biochemical and Structural Characterization of the Human TL1A Ectodomain,

(2009) Chenyang Zhan et al.   BIOCHEMISTRY

Structural Basis for the Lack of E2 Interaction in the RING Domain of TRAF2

(2009) Qian Yin et al.   BIOCHEMISTRY

Regulation of TNFRSF and innate immune signalling complexes by TRAFs and cIAPs

(2009) J Silke et al.   CELL DEATH AND DIFFERENTIATION

The Structure of the Trimer of Human 4-1BB Ligand Is Unique among Members of the Tumor Necrosis Factor Superfamily

(2009) Eun-Young Won et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells

(2009) D. V. Rozanov et al.   MOLECULAR CANCER THERAPEUTICS

The Fas–FADD death domain complex structure unravels signalling by receptor clustering

(2009) Fiona L. Scott et al.   NATURE

E2 interaction and dimerization in the crystal structure of TRAF6

(2009) Qian Yin et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Evolution of GITRL immune function: Murine GITRL exhibits unique structural and biochemical properties within the TNF superfamily

(2008) K. Chattopadhyay et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA